Invesco Ltd. Increases Stock Holdings in Organogenesis $ORGO

Key Points

• Invesco Ltd. significantly increased its stake in Organogenesis by 779.7% in the first quarter, acquiring an additional 947,705 shares, bringing its total holdings to over 1 million shares valued at approximately $4.62 million.
• Organogenesis reported an EPS of ($0.09) for the latest quarter, missing analysts' expectations, and posted a revenue of $101.01 million, below the consensus estimate of $104.75 million.
• Analysts have mixed sentiments on the stock, with a few rating it as a "Buy" and a revised price target set at $9.00 by Cantor Fitzgerald, while the average target remains at $7.50.

Invesco Ltd. boosted its position in Organogenesis (NASDAQ:ORGO - Free Report) by 779.7% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,069,252 shares of the company's stock after purchasing an additional 947,705 shares during the quarter. Invesco Ltd. owned approximately 0.84% of Organogenesis worth $4,619,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Merit Financial Group LLC acquired a new position in shares of Organogenesis during the first quarter valued at about $45,000. ProShare Advisors LLC increased its holdings in shares of Organogenesis by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 20,329 shares of the company's stock valued at $65,000 after acquiring an additional 6,689 shares in the last quarter. Victory Capital Management Inc. acquired a new position in shares of Organogenesis during the first quarter valued at about $67,000. Algert Global LLC acquired a new position in shares of Organogenesis during the fourth quarter valued at about $69,000. Finally, PDT Partners LLC acquired a new position in shares of Organogenesis during the fourth quarter valued at about $110,000. 49.57% of the stock is currently owned by institutional investors.

Insider Activity

In other Organogenesis news, insider Lori Freedman bought 142,379 shares of the firm's stock in a transaction dated Thursday, June 5th. The shares were purchased at an average price of $2.91 per share, for a total transaction of $414,322.89. Following the transaction, the insider directly owned 837,437 shares of the company's stock, valued at approximately $2,436,941.67. This represents a 20.48% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In the last 90 days, insiders purchased 252,264 shares of company stock worth $725,732. Company insiders own 33.00% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on ORGO shares. BTIG Research reiterated a "buy" rating on shares of Organogenesis in a research report on Tuesday, July 15th. Cantor Fitzgerald upped their target price on Organogenesis from $7.00 to $9.00 and gave the company an "overweight" rating in a research report on Friday, August 8th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $7.50.

Organogenesis Trading Down 3.6%

Organogenesis stock traded down $0.19 during mid-day trading on Tuesday, hitting $4.97. The company had a trading volume of 312,656 shares, compared to its average volume of 1,397,443. Organogenesis has a 12-month low of $2.45 and a 12-month high of $6.71. The company's fifty day moving average is $4.50 and its 200-day moving average is $4.19. The company has a market capitalization of $629.86 million, a price-to-earnings ratio of -35.46 and a beta of 1.75.

Organogenesis (NASDAQ:ORGO - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.08). Organogenesis had a negative return on equity of 0.37% and a negative net margin of 1.92%.The company had revenue of $101.01 million during the quarter, compared to analysts' expectations of $104.75 million. Organogenesis has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Organogenesis will post -0.07 EPS for the current fiscal year.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.